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January 2013286 Abstractsmethods of vessel control, which may be particularly important in patients
with calcified distal vessels.
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Background: The use of an arteriovenous fistula (AVF) for haemodi-
alysis treatment may be associated with a high early failure rate, but usually
good long-term patency, while using an arteriovenous graft (AVG) yields a
lower early failure rate with worse long-term patency. The aim of this study
was to calculate and compare the costs and outcome of AVF and AVG
surgery in terms of early and long-term patencies.
rMethods: A decision tree and a Markov model were constructed to
alculate costs and performance of AVFs and AVGs. The model was popu-
ated with a retrospective cohort of HD patients receiving their first VA. The
utcomes were determined probabilistically with a 5-year follow-up.
Results: AVFs were usable for a mean (95% CI) of 28.5 months
24.6–32.5 months), while AVGs showed a patency of 25.5 months (20.0–
1.2 months). The use of AVFs was the dominant type of VA and €631
ould be saved per patient/per month patency compared to AVG use.
egardless of the willingness to pay, the use of AVFs yielded a higher
robability of being cost-effective compared to AVGs.
Conclusions: AVFs are more cost-effective than AVGs. Nonetheless,
arly failure rates significantly influence AVF performance and initiatives to
educe early failure can improve its cost-effectiveness.
